Clinical trials: Neoplasms of Prostate
Prostate Cancer
Understanding of Genetics by Men at Risk for Prostate Cancer
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions.
- Trial name
- NCT04550845
- Testing
- Focus group analyses
- Where
- 3 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Tobacco Use Disorder
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens.
- Trial name
- NCT00158145
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Metastatic Castration-resistant Prostate Cancer
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo…
- Trial name
- NCT03403595
- Testing
- 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
Around 375,000 cancers are diagnosed in the UK annually, with this figure expected to reach 500,000 by 2035. As the number of different cancer treatment options and our scientific understanding continue to grow rapidly, it can be…
- Trial name
- PROSAIC-DS (NCT05355727)
- Testing
- Clinical decision support tool recommended outcome
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Prostate Cancer
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects…
- Trial name
- NCT03995888
- Testing
- rhPSMA-7.3 (18F) Injection
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
An Exploration of Genetic Testing for Prostate Cancer Susceptibility
Study of the factors that affect interest in - and uptake of - genetic testing for variants that predispose to prostate cancer from the perspective of the patient.
- Trial name
- NCT00997464
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust